Literature DB >> 25434580

Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data.

Julia L Williams1, Peter A Greer1, Jeremy A Squire2.   

Abstract

We present a meta-analysis of somatic copy number alterations (CNAs) from 11 publications that examined 662 prostate cancer patient samples, which were derived from 546 primary and 116 advanced tumors. Normalization, segmentation, and identification of corresponding CNAs for meta-analysis was achieved using established commercial software. Unsupervised analysis identified five genomic subgroups in which approximately 90% of the samples were characterized by abnormal profiles with gains of 8q. The most common loss was 8p (NKX3.1). The CNA distribution in other genomic subgroups was characterized by losses at 2q, 3p, 5q, 6q, 13q, 16q, 17p, 18q, and PTEN (10q), and acquisition of 21q deletions associated with the TMPRSS2-ERG fusion rearrangement. Parallel analysis of advanced and primary tumors in the cohort indicated that genomic deletions of PTEN and the gene fusion were enriched in advanced disease. A supervised analysis of the PTEN deletion and the fusion gene showed that PTEN deletion was sufficient to impose higher levels of CNA. Moreover, the overall percentage of the genome altered was significantly higher when PTEN was deleted, suggesting that this important genomic subgroup was likely characterized by intrinsic chromosomal instability. Predicted alterations in expression levels of candidate genes in each of the recurrent CNA regions characteristic of each subgroup showed that signaling networks associated with cancer progression and genome stability were likely to be perturbed at the highest level in the PTEN deleted genomic subgroup.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Array CGH; bioinformatics; genomic instability; pI3 kinase; tumor suppressor

Mesh:

Year:  2014        PMID: 25434580     DOI: 10.1016/j.cancergen.2014.09.003

Source DB:  PubMed          Journal:  Cancer Genet


  38 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

2.  A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition.

Authors:  Nathan Bucay; Divya Bhagirath; Kirandeep Sekhon; Thao Yang; Shinichiro Fukuhara; Shahana Majid; Varahram Shahryari; ZLaura Tabatabai; Kirsten L Greene; Yutaka Hashimoto; Marisa Shiina; Soichiro Yamamura; Yuichiro Tanaka; Guoren Deng; Rajvir Dahiya; Sharanjot Saini
Journal:  Cell Death Differ       Date:  2017-05-12       Impact factor: 15.828

3.  Landscape of Genomic Alterations in Pituitary Adenomas.

Authors:  Wenya Linda Bi; Peleg Horowitz; Noah F Greenwald; Malak Abedalthagafi; Pankaj K Agarwalla; Wiliam J Gibson; Yu Mei; Steven E Schumacher; Uri Ben-David; Aaron Chevalier; Scott Carter; Grace Tiao; Priscilla K Brastianos; Azra H Ligon; Matthew Ducar; Laura MacConaill; Edward R Laws; Sandro Santagata; Rameen Beroukhim; Ian F Dunn
Journal:  Clin Cancer Res       Date:  2016-10-05       Impact factor: 12.531

4.  A copy number gain on 18q present in primary prostate tumors is associated with metastatic outcome.

Authors:  Keith A Ashcraft; Teresa L Johnson-Pais; Dean A Troyer; Javier Hernandez; Robin J Leach
Journal:  Urol Oncol       Date:  2020-07-12       Impact factor: 3.498

5.  MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer.

Authors:  Andreas Pettersson; Travis Gerke; Kathryn L Penney; Rosina T Lis; Edward C Stack; Nelma Pértega-Gomes; Giorgia Zadra; Svitlana Tyekucheva; Edward L Giovannucci; Lorelei A Mucci; Massimo Loda
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

6.  DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer.

Authors:  Daniela Kurfurstova; Jirina Bartkova; Radek Vrtel; Alena Mickova; Alena Burdova; Dusana Majera; Martin Mistrik; Milan Kral; Frederic R Santer; Jan Bouchal; Jiri Bartek
Journal:  Mol Oncol       Date:  2016-03-03       Impact factor: 6.603

7.  Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of β-catenin in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2017-07-24       Impact factor: 4.553

8.  Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.

Authors:  Adam G Sowalsky; Haydn T Kissick; Sean J Gerrin; Rachel J Schaefer; Zheng Xia; Joshua W Russo; M Simo Arredouani; Glenn J Bubley; Martin G Sanda; Wei Li; Huihui Ye; Steven P Balk
Journal:  Clin Cancer Res       Date:  2017-01-24       Impact factor: 12.531

9.  MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Karsten Salomo; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-25       Impact factor: 4.553

10.  Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.

Authors:  Habiba Elfandy; Joshua Armenia; Filippo Pederzoli; Eli Pullman; Nelma Pertega-Gomes; Nikolaus Schultz; Kartik Viswanathan; Aram Vosoughi; Mirjam Blattner; Konrad H Stopsack; Giorgia Zadra; Kathryn L Penney; Juan Miguel Mosquera; Svitlana Tyekucheva; Lorelei A Mucci; Christopher Barbieri; Massimo Loda
Journal:  Mol Cancer Res       Date:  2018-10-17       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.